Ina Sulkaj

Ina Sulkaj

Auto-generated profile, based on publicly available information

Ina Sulkaj

Transplantation Research Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SESiawosh K. Eskandari
Siawosh K. Eskandari
ISIna Sulkaj
Ina Sulkaj
MMMariane Bandeira Melo
Mariane Bandeira Melo
NLNa Li
Na Li
HAHazim Allos
Hazim Allos
JAJamil Azzi
Jamil Azzi
Adoptive cell transfer of ex vivo expanded regulatory T cells (Tregs) has shown immense potential in animal models of auto- and alloimmunity. However, the effective translation of such Treg therapies to the clinic has been slow. Because Treg homeostasis is known to require continuous T cell receptor (TCR) ligation and exogenous interleukin-2 (IL-2), some investigators have explored the use of low-dose IL-2 injections to increase endogenous Treg responses. Systemic IL-2 immunotherapy, however, can also lead to the activation of cytotoxic T lymphocytes and natural killer cells, causing adverse therapeutic outcomes. Here, we describe a drug delivery platform, which can be engineered to autostimulate Tregs with IL-2 in response to TCR-dependent activation, and thus activate these cells in sites of antigen encounter. To this end, protein nanogels (NGs) were synthesized with cleavable bis(N-hydroxysuccinimide) cross-linkers and IL-2/Fc fusion (IL-2) proteins to form particles that release IL-2 under reducing conditions, as found at the surface of T cells receiving stimulation through the TCR. Tregs surface-conjugated with IL-2 NGs were found to have preferential, allograft-protective effects relative to unmodified Tregs or Tregs stimulated with systemic IL-2. We demonstrate that murine and human NG–modified Tregs carrying an IL-2 cargo perform better than conventional Tregs in suppressing alloimmunity in murine and humanized mouse allotransplantation models. In all, the technology presented in this study has the potential to improve Treg transfer therapy by enabling the regulated spatiotemporal provision of IL-2 to antigen-primed Tregs.

28 February 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JCJohn Y. Choi
John Y. Choi
SESiawosh K. Eskandari
Siawosh K. Eskandari
SCSongjie Cai
Songjie Cai
ISIna Sulkaj
Ina Sulkaj
JAJean Pierre Assaker
Jean Pierre Assaker
JAJamil Azzi
Jamil Azzi
Significance: There is increasing evidence that CD8 + regulatory T cells (CD8 Treg) can modulate the immune response in the context of autoimmune disease, infection, and cancer. Here we asked whether this regulatory mechanism might control the host response to transplanted heart allografts. We report that CD8 Treg that recognize Qa-1, the murine homolog of HLA-E, strongly inhibits host production of antibodies specific for the donor organ. Since the production of antidonor antibodies is currently a major barrier to successful transplantation, identification of this Qa-1/HLA-E-dependent pathway may pave the way to approaches to this pressing clinical problem.